July 1, 2025

Claire Mazumdar is today’s guest on The Long Run. She is the founding CEO of Boston-based Bicara Therapeutics. Bicara is developing a bifunctional antibody for head and neck cancer. It’s called ficerafusp alfa, and it’s designed to bind with a couple of well-known biological targets, EGFR and TGF-beta. The idea is to block a well-known cancer driver in EGFR, while... Read More